oxfendazole has been researched along with Cancer of Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Huang, L; Huang, S; Li, L; Li, Z; Ou, Y; Tang, W; Wen, C; Wu, S; Wu, Z; Xiang, Y; Ye, W; Zhong, S; Zhou, C | 1 |
| Huang, Z; Jiang, C; Tian, W; Xu, D; Zheng, S | 1 |
2 other study(ies) available for oxfendazole and Cancer of Lung
| Article | Year |
|---|---|
Oxfendazole Induces Apoptosis in Ovarian Cancer Cells by Activating JNK/MAPK Pathway and Inducing Reactive Oxygen Species Generation.
Topics: Anthelmintics; Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; Ovarian Neoplasms; Reactive Oxygen Species | 2023 |
The anthelmintic agent oxfendazole inhibits cell growth in non‑small cell lung cancer by suppressing c‑Src activation.
Topics: Apoptosis; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; CSK Tyrosine-Protein Kinase; Enzyme Activation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Signal Transduction; src-Family Kinases | 2019 |